The investigation of the effect of fraxin on hepatotoxicity induced by cisplatin in rats

Document Type : Original Article


1 Department of Nutrition and Dietetics, High School of Health, Ağrı İbrahim Çeçen University, Ağrı, Turkey

2 Department of First and Emergency Aid, Health Services Vocational High School, Ağrı İbrahim Çeçen University, Ağrı, Turkey

3 Department of Pathology, Faculty of Veterinary, Atatürk University, Erzurum, Turkey

4 Department of Biochemistry, Faculty of Veterinary, Atatürk University, Erzurum, Turkey


Objective(s): This study was designed to assess the effect of fraxin which has various biological properties against liver injury induced by cisplatin.
Materials and Methods: In our study, 24 Wistar albino rats were randomly assigned to control, fraxin, cisplatin, and fraxin+cisplatin groups. Cisplatin 12 mg/kg IP and fraxin 40 mg/kg orally were applied. When the experiment ended, the rats were sacrificed and the liver tissues were taken rapidly. Liver tissue specimens were maintained under appropriate conditions. Later, biochemical, histopathological, and immunohistochemical evaluations were performed.
Results: According to our biochemical findings, oxidant parameters increased while antioxidant parameters decreased in cisplatin group compared with control group. Antioxidant parameters increased but oxidant parameters decreased in fraxin + cisplatin group compared with the cisplatin group. Immunohistochemical evaluations showed that the expressions of TNF-α and Caspase-3 were negative in control and fraxin groups, whereas severe levels were found in the cisplatin group. However, it was determined that the expressions of TNF-α and Caspase-3 were in mild levels in fraxin + cisplatin treatment group. In addition, it was observed that the increase of pathological markers such as coagulation necrosis, hydropic degeneration, dilatation in sinusoid, and hyperemia in the cisplatin group were compatible with our biochemical and immunohistochemical findings.
Conclusion: Biochemical, immunohistochemical, and histopathological results revealed that fraxin was effective in relieving cisplatin-induced liver damage.


1. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963; 105:574-578.
2. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24:19-38.
3. Ekinci Akdemir FN, Albayrak M, Calik M, Bayir Y, Gulcin I. The protective effects of p-coumaric acid on acute liver and kidney damages induced by cisplatin. Biomedicines 2017; 5: 18-28.
4. Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, et al. Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int 2014; 2014:1-7.
5. Atessahin A, Karahan I, Turk G, Gur S, Yilmaz S, Ceribasi AO. Protective role of lycopene on cisplatin-induced changes in sperm characteristics, testicular damage and oxidative stress in rats. Reprod Toxicol 2006; 21:42-47.
6. Gomez-Sierra T, Eugenio-Perez D, Sanchez-Chinchillas A, Pedraza-Chaverri J. Role of food-derived anti-oxidants against cisplatin induced-nephrotoxicity. Food Chem Toxicol 2018; 120:230-242.
7. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57:715-724.
8. Guemouri L, Artur Y, Herbeth B, Jeandel C, Cuny G, Siest G. Biological variability of superoxide-dismutase, glutathione-peroxidase, and atalase in blood. Clin Chem 1991; 37:1932-1937.
9. Bentli R, Parlakpinar H, Polat A, Samdanci E, Sarihan ME, Sagir M. Molsidomine prevents cisplatin-induced hepatotoxicity. Arch Med Res 2013; 44:521-528.
10.    Yadav YC. Hepatoprotective effect of ficus religiosa latex on cisplatin induced liver injury in Wistar rats. Rev Bras Farmaco-Braz J Pharmacog 2015; 25:278-283.
11.    Chang BY, Jung YS, Yoon CS, Oh JS, Hong JH, Kim YC, et al. Fraxin prevents chemically induced hepatotoxicity by reducing oxidative stress. Molecules 2017; 22: 587-599.
12.    Kimura Y, Sumiyoshi M. Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G(1) arrest in tumor cells. Eur J Pharmacol 2015; 746:115-125.
13.    Li JM, Zhang X, Wang X, Xie YC, Kong LD. Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice. Eur J Pharmacol 2011; 666:196-204.
14.    Medina ME, Iuga C, Alvarez-Idaboy JR. Anti-oxidant activity of fraxetin and its regeneration in aqueous media. A density functional theory study. Rsc Advances 2014;4:52920-52932.
15.    Molina-Jimenez MF, Sanchez-Reus MI, Andres D, Cascales M, Benedi J. Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. Brain Res 2004; 1009:9-16.
16.    Niu X, Liu F, Li W, Zhi W, Yao Q, Zhao J, et al. Hepatoprotective effect of fraxin against carbon tetrachloride-induced hepatotoxicity in vitro and in vivo through regulating hepatic anti-oxidant, inflammation response and the MAPK-NF-κB signaling pathway. Biomed Pharmacother 2017; 95:1091-1102.
17.    Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 1966; 16:359-364.
18.    Sun Y, Oberley LW, Li Y. A Simple method for clinical assay of superoxide-dismutase. Clin Chem 1988; 34:497-500.
19.    Aebi H. Catalase in vitro. Methods Enzymol 1984; 105:121-126.
20.    Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25:192-205.
21.    Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Communi  2012; 425:503-509.
22.    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
23.    Ekinci-Akdemir FN, Yildirim S, Kandemir FM, Gulcin I, Kucukler S, Saglam YS, et al. The effects of casticin and myricetin on liver damage induced by methotrexate in rats. Iran J Basic Med  Sci 2018; 21:1281-1288.
24.    Boroja T, Katanic J, Rosic G, Selakovic D, Joksimovic J, Misic D, et al. Summer savory (Satureja hortensis L.) extract: Phytochemical profile and modulation of cisplatin-induced liver, renal and testicular toxicity. Food Chem Toxicol 2018; 118:252-263.
25.    Bunel V, Antoine MH, Nortier J, Duez P, Stevigny C. Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from Angelica sinensis against cisplatin toxicity in vitro. Toxicol in Vitro 2015; 29:458-467.
26.    Ekinci-Akdemir FN, Gulcin I, Gursul C, Alwasel SH, Bayir Y. Effect of P-coumaric acid against oxidative stress induced by cisplatin in brain tissue of rats. J Animal Plant Sci 2017; 27:1560-1564.
27.    Kilic K, Sakat MS, Akdemir FNE, Yildirim S, Saglam YS, Askin S. Protective effect of gallic acid against cisplatin-induced ototoxicity in rats. Braz J Otorhinolaryngol 2019; 85: 267-274.
28.    Sherif IO, Abdel-Aziz A, Sarhan OM. Cisplatin-induced testicular toxicity in rats: the protective effect of arjunolic acid. J Biochem Mol Toxicol  2014; 28:515-521.
29.    Blumberg J. Use of biomarkers of oxidative stress in research studies. J Nutr 2004; 134:3188-3189.
30.    Martins NM, Santos NAG, Curti C, Bianchi MLP, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J App Toxicol 2008; 28:337-344.
31.    Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Communi 1994; 203:1175-1180.
32.    Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998; 131:518-526.
33.    Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and anti-oxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160:1-40.
34.    Gulcin I. Anti-oxidant activity of food constituents: an overview. Archi Toxicol  2012; 86:345-391.
35.    Nagi MN, Almakki HA. Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity. Phytother  Res 2009; 23:1295-1298.
36.    Miyashita T, Reed JC. Tumor-suppressor P53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299.
37.    Huang HB, Shen ZH, Geng QQ, Wu ZH, Shi PY, Miao XQ. Protective effect of Schisandra chinensis bee pollen extract on liver and kidney injury induced by cisplatin in rats. Biomed Pharmacother  2017; 95:1765-1776.
38.    Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mut Res Fund Mol M 2003; 531:81-92.
39.    Springer JE, Azbill RD, Nottingham SA, Kennedy SE. Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J Neurosci  2000; 20:7246-7251.
40.    Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci  1997; 17:7415-7424.
41.    Alibakhshi T, Khodayar MJ, Khorsandi L, Rashno M, Zeidooni L. Protective effects of zingerone on oxidative stress and inflammation in cisplatin-induced rat nephrotoxicity. Biomed Pharmacother 2018; 105:225-232.
42.    Ueki M, Ueno M, Morishita J, Maekawa N. Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. J Biosci Bioeng  2013; 115:547-551.
43.    Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicol  2007; 230:256-264.
44.    Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell  Biochem 2005; 278:79-84.